C-reactive protein and incidence of type 2 diabetes in the Pizarra study

European Journal of Clinical Investigation

Volumn 43, Issue 2, 2013, Pages 159-167

  Rubio Martín, Elehazara ^a,b,c   Soriguer, Federico ^a,b,c   Gutiérrez Repiso, Carolina ^a,b,c   Garrido Sánchez, Lourdes ^a,b,c   de Adana, Marisol S Ruíz ^a,b,c   García Fuentes, Eduardo ^a,b,c   Morcillo, Sonsoles ^b,e   Esteva, Isabel ^a,b,c   Chaves, Felipe J ^b,d   Rojo Martinez, Gemma ^a,b,c  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina IBIMA Plataforma Bionand   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Adipokines; Adiponectin; Cytokines; Hs C reactive protein; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FATTY ACID BINDING PROTEIN 4; HEMOGLOBIN A1C; INTERLEUKIN 6; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGE; ARTICLE; CARBOHYDRATE METABOLISM; FEMALE; FOLLOW UP; GENDER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; WAIST HIP RATIO;

ADIPONECTIN; ADULT; C-REACTIVE PROTEIN; COHORT STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; LEPTIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPAIN; STATISTICS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872605324     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12027     Document Type: Article

References (43)

1. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
2. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
3. Riaz M, Fawwad A, Hydrie MZ, Basit A, Shera AS. Is there any association of serum high-sensitivity C-reactive protein with various risk factors for metabolic syndrome in a healthy adult population of Karachi, Pakistan? Metab Syndr Relat Disord 2011;9:177-82.
4. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
5. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93-9.
6. Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005;28:2497-500.
7. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004;47:1403-10.
8. Liu S, Tinker L, Song Y, Rifai N, Bonds DE, Cook NR et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med 2007;167:1676-85.
9. Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009;52:1040-7.
10. Hu G, Jousilahti P, Tuomilehto J, Antikainen R, Sundvall J, Salomaa V. Association of serum C-reactive protein level with sex-specific type 2 diabetes risk: a prospective Finnish study. J Clin Endocrinol Metab 2009;94:2099-105.
11. Dehghan A, Kardys I, De Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007;56:872-8.
12. Soriguer F, Rojo-Martinez G, Almaraz MC, Esteva I, Ruiz de Adana MS, Morcillo S et al. Incidence of type 2 diabetes in southern Spain (Pizarra Study). Eur J Clin Invest 2008;38:126-33.
13. WHO Expert Committee. Physical status: the use and interpretation of anthropometry Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452.
14. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
15. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
17. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34:2-11.
18. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007;115:1537-43.
19. Chen BH, Song Y, Ding EL, Roberts CK, Manson JE, Rifai N et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care 2009;32:329-34.
20. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
21. Feng RN, Zhao C, Sun CH, Li Y. Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS ONE 2011;6:e18480.
22. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007;30:2667-72.
23. Erbay E, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins in metabolic syndrome. Curr Atheroscler Rep 2007;9:222-9.
24. Aragones G, Ferre R, Lazaro I, Cabre A, Plana N, Merino J et al. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis 2010;213:329-31.
25. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007;30:1200-5.
26. Schmidt MI, Duncan BB, Vigo A, Pankow JS, Couper D, Ballantyne CM et al. Leptin and incident type 2 diabetes: risk or protection? Diabetologia 2006;49:2086-96.
27. Soderberg S, Zimmet P, Tuomilehto J, Chitson P, Gareeboo H, Alberti KG et al. Leptin predicts the development of diabetes in Mauritian men, but not women: a population-based study. Int J Obes (Lond) 2007;31:1126-33.
28. Sun Q, Van Dam RM, Meigs JB, Franco OH, Mantzoros CS, Hu FB. Leptin and soluble leptin receptor levels in plasma and risk of type 2 diabetes in U.S. women: a prospective study. Diabetes 2010;59:611-8.
29. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004;53:2473-8.
30. Li S, Shin HJ, Ding EL, Van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179-88.
31. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004;27:1680-7.
32. Yuan G, Chen X, Ma Q, Qiao J, Li R, Li X et al. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 2007;194:275-81.
33. Soriguer F, Rubio-Martin E, Fernandez D, Valdes S, Garcia-Escobar E, Martin-Nunez GM et al. Testosterone, SHBG and risk of type 2 diabetes in the second evaluation of the Pizarra cohort study. Eur J Clin Invest 2012;42:79-85.
34. Soriguer F, Goday A, Bosch-Comas A, Bordiu E, Calle-Pascual A, Carmena R et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Diabeties Study. Diabetologia 2011;55:88-93.
35. Hussain A, Claussen B, Ramachandran A, Williams R. Prevention of type 2 diabetes: a review. Diabetes Res Clin Pract 2007;76:317-26.
36. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:299.
37. Herder C, Baumert J, Zierer A, Roden M, Meisinger C, Karakas M et al. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS ONE 2011;6:e19852.
38. Chao C, Song Y, Cook N, Tseng CH, Manson JE, Eaton C et al. The lack of utility of circulating biomarkers of inflammation and endothelial dysfunction for type 2 diabetes risk prediction among postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med 2010;170:1557-65.
39. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329-39.
40. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008;14:741-51.
41. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:E527-33.
42. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011;342:d548.
43. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359(18):1897-908.